Risposta Consulting
New Perspective, New Reality
Associates
Medical Affairs Associates at Risposta Consulting, offering specialized expertise in medical affairs and pharmacovigilance.
Eric Heegaard is a board-certified medical specialist with a profound blend of academic achievement and extensive experience across the healthcare and pharmaceutical industries. With a PhD, DMSc, and an Executive Master of Business Strategy, he is a seasoned clinician and pharmaceutical executive, skilled in all phases of drug development and commercialization.
​
Eric founded MedPro Consulting in 2024, a firm dedicated to advancing clinical development, medical affairs, and strategic programs. Prior to this, he served as the lead medical expert at Evaxion Biotech, where he was instrumental in the strategic planning and operational implementation of their clinical pipeline and medical affairs activities. His leadership helped achieve milestones such as the establishment of a clinical development unit, initiation of global clinical trials, and significant partnerships, including a $15 million contract with Merck.
​
From 2020 to 2021, Eric took on the role of Medical Director for the Nordics, UK & Ireland at Seagen, where he successfully launched medical affairs activities and commercialized new products rapidly post-EMA approval.
His tenure as Nordic Medical Director from 2017 to 2020 saw him driving substantial growth, expanding the team, and enhancing scientific collaborations across the region.
Earlier in his career, Eric contributed to global medical strategy as an International Medical Director and engaged in high-level biosecurity projects at Sandia National Laboratories.
His academic pursuits and practical experiences have made him a trusted leader in medical strategy and innovation.
​
Eric's commitment to excellence is also evident in his contributions to numerous medical journals and his involvement in postgraduate training and board roles.
His strategic acumen and leadership in medical affairs make him an invaluable asset to any organization seeking to navigate the complexities of the healthcare sector.
Gitte is an accomplished and highly skilled professional with a diverse and extensive background in the pharmaceutical and clinical research sectors. Her career trajectory reflects a relentless commitment to excellence, evolving from her initial practice as a registered nurse to an authority in quality assurance and regulatory compliance within the global pharmaceutical industry.
​
Her academic journey commenced with history studies at the University of Copenhagen, where she laid the foundation for her analytical and meticulous approach to research and data interpretation. This was further enriched by her training as a registered nurse at Frederiksberg Hospital, which provided her with firsthand clinical experience and a profound understanding of patient care and medical protocols.
​
Gitte's adeptness at bridging the gap between clinical practices and quality management is underscored by her diplomas in pharmacology and specialized business studies, as well as her international certifications as an ISO 9000 Certified Lead Auditor and her Master's degree in Quality Management from Anglia Polytechnic University, Cambridge, which she passed with distinction.
​
Throughout her career, Gitte has been entrusted with pivotal roles, most notably her long-standing tenure as the Senior Director of Corporate Quality Audits at Ferring Pharmaceuticals. Here, she orchestrated comprehensive audit programs and led teams across multiple continents, reflecting her ability to manage and implement strategic initiatives on a global scale. Her responsibilities were vast and crucial for ensuring compliance with Good Clinical Practice (GCP), reinforcing her position as a vanguard in the field.
​
Her role encompassed the surveillance of corrective actions, fostering quality improvements, and managing risk assessments in concert with audit programs. Moreover, Gitte's proficiency was not limited to audits; she was pivotal in preparing for and participating in regulatory inspections and training new auditors, thereby contributing to the edification and upholding of industry standards.
​
Gitte's expertise is further evidenced by her selection for the Senior Correspondent Team for the "Clinical Research/Clinical Quality Assurance Advisor" journal, a role that underscores her respected voice in the industry.
Her commitment to professional growth and contribution is marked by an impressive array of courses, conferences, and workshops that she not only attended but also often led as a trainer and speaker. Gitte has been an integral part of the quality assurance community, sharing her knowledge generously with peers through her involvement with the Danish Association of Good Clinical Practice and the Association of Clinical Research Professionals, among others.
​
As an independent consultant since 2018, Gitte has continued to leverage her wealth of knowledge, offering her expertise to a broader audience. Her work is hallmarked by an exceptional blend of clinical knowledge, quality assurance proficiency, and regulatory savvy, making her a distinguished figure in her field. This is reflected in her acknowledgment in "Who's Who in Science and Engineering", an honor that recognizes her significant contributions and her standing as a leader in the world of clinical research and pharmaceutical quality assurance.
Hans Henrik is a distinguished professional with a rich and varied career spanning the medical and research sectors. His journey reflects a steadfast commitment to excellence, beginning with 15 years of clinical practice in diverse medical departments, culminating in specialized roles in infectious diseases and clinical microbiology.
​
His academic foundation was laid at the University of Copenhagen, where he pursued medical studies, honing his analytical skills and clinical expertise. This was complemented by extensive training and licensure as a board-certified specialist in clinical medical microbiology, a testament to his dedication to advancing his field.
​
Hans Henrik's commitment to continuous learning led him to undertake a prestigious 2.5-year Fellowship at the Clinical Center of the National Institutes of Health in Maryland, USA, where he further enriched his knowledge and expertise.
​
Throughout his career, Hans Henrik has held pivotal roles, demonstrating his ability to manage complex challenges and drive initiatives to success. His expertise in bridging clinical practices with research and specialized medical roles underscores his standing as a respected authority in the medical field.
​
As an independent consultant, Hans Henrik continues to leverage his wealth of experience, offering his expertise to a broader audience. His work is characterized by a unique blend of clinical knowledge, research proficiency, and strategic acumen, making him a highly sought-after figure in his field.
Elden's career is marked by significant roles and achievements. As a Patient-Reported Outcomes Expert at a German pharma, he played a pivotal role in a global clinical trial, leading to its successful approval. His clinical research expertise has been instrumental in advancing studies in oncology, hematology, CNS, and inflammation.
​
In neuroscience, Elden's tenure as an Area Medical Advisor for a US based pharma, worked on new medical insight, demonstrating his deep expertise and strategic medical leadership.
​
As a prelaunch strategist for numerous companies, Elden's strategic acumen in medical affairs shone through in the planning and execution of study activities, especially in oncology.
His work as a Global Medical Reviewer for companies further highlights his commitment to ensuring the quality and compliance of medical materials.
​
Collaborating with a US pharma company, Elden revolutionized communication strategies in the U.S. market, integrating innovative ideas and digital tools to effectively engage healthcare professionals.
Elden's personal expertise is characterized by his innovative and strategic approach in medical affairs, integrating technology with medical science, and collaborative leadership.
His proactive project management and visionary ideas have significantly impacted healthcare challenges.
​
In addition to his professional achievements, Dr. Elden's educational background includes completing his education in behavioral science at the Norwegian University of Science and Technology (NTNU) and earning a doctorate in psychology from the University of Tromsø.
His academic work, including pioneering digital learning and contributing to neurophysiology, complements his extensive career in the pharmaceutical industry.
​
Dr. Elden’s multifaceted career, encompassing leadership, innovation, and research, has solidified his status as a leading figure in both scientific and pharmaceutical realms.
His contributions have not only deepened our understanding of complex medical processes but have also paved the way for innovative treatment and management approaches in various health conditions
Dr. Christina Östberg Lloyd is a distinguished medical professional and executive with an extensive career spanning over three decades. Born in Sweden, she graduated with a Medical Doctor degree from Lund University in 1988 and is a specialist in Gynecology, Obstetrics, and Reproductive Medicine since 1997. Dr. Lloyd is fluent in Swedish, Scandinavian languages, and English, and has an understanding of German.
​
Her career is marked by various leadership roles in the healthcare and pharmaceutical sectors, covering clinical research, medical affairs, regulatory/safety/quality affairs, and leadership development. From 1988 to 2002, she worked as a physician in Swedish hospitals, focusing on women's health, obstetrics, and surgery. Her journey in the pharmaceutical industry began at Ferring Pharmaceuticals as Nordic Medical Affairs Director (2002-2009), followed by a role as Clinical Medical Regulatory Director at Novo Nordisk Scandinavia (2009-2020).
​
In 2020, Dr. Lloyd became the CEO of Pharmiva AB, a FemTech startup, and successfully led its IPO on Nasdaq First North. Since 2022, she has held the position of Senior Vice President and Global Head of Reproductive Medicine and Maternal Health at Ferring Pharmaceuticals. Here, she has been instrumental in developing and operationalizing global strategies, covering aspects from clinical research to preparing the market for commercial launch.
​
Dr. Lloyd's engagement extends beyond corporate roles. She actively participates in Swedish and Danish Life Science, demonstrating her commitment through her involvement in LIF (the trade association for the research-based pharmaceutical industry in Sweden) and as Chairwoman of the Board in SWElife, a VINNOVA strategic innovation area. Her involvement in these organizations highlights her dedication to fostering innovation and collaboration in the life sciences sector.
​
Additionally, Dr. Lloyd has made significant contributions to academia and industry organizations. She has been a part of several advisory boards and committees, focusing on life sciences, healthcare, and pharmaceuticals. Her board membership at Spermosens AB and engagement with the Life Science Innovation Board at Lund University further underscore her extensive involvement in the field.
​
Her educational achievements are also noteworthy, with programs in medical business strategy, corporate governance, executive leadership, and business management from prestigious institutions like SIMI, EFL, HBR, IMD Business School, and Nasdaq.
​
Overall, Dr. Lloyd's career is characterized by her unwavering commitment to advancing healthcare and pharmaceutical innovation, reflected in her significant contributions to both clinical practice and corporate leadership in the medical field.
Dr. Hans Chr. Siersted, born in 1956, is a seasoned medical professional, certified specialist in pulmonary diseases, allergology, and medical education. A graduate of Odense University, Denmark, he has an impressive career spanning clinical practice, academia, and regulatory consulting.
Dr. Siersted leverages his expertise in pulmonary medicine, gained through significant roles in Danish universities and hospitals, including as Head of Pulmonary Medicine at both Roskilde and Odense University Hospitals.
He also served as a Nordic Cluster Medical Lead for GSK and a Chief Medical Officer at the Danish Medicines Agency.
​
Most recently, he served for almost 5 years at the Danish Medicines Agency, supervising regulatory post-marketing procedures for a multitude of products on the European level. As a national delegate and rapporteur in EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) he gained deep insights in EMA’s procedures, strategies and ways-of-working and developed close professional relationships with representatives from EMA and delegations from Medicines Agencies in Europe and beyond.
​
Known for his ethical integrity and empathic approach, Dr. Siersted has contributed significantly to medical boards and societies.
​
He is an active researcher with an H-index of 22 and has engaged in multiple collaborations with the medical industry.
​